| Literature DB >> 17909052 |
Xiaoping Zhang1, Liang Zhang, Hongmei Yang, Xu Huang, Hasan Otu, Towia A Libermann, William C DeWolf, Roya Khosravi-Far, Aria F Olumi.
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo-2L promotes apoptosis in cancer cells while sparing normal cells. Although many cancers are sensitive to TRAIL-induced apoptosis, some evade the proapoptotic effects of TRAIL. Therefore, differentiating molecular mechanisms that distinguish between TRAIL-sensitive and TRAIL-resistant tumors are essential for effective cancer therapies. Here, we show that c-Fos functions as a proapoptotic agent by repressing the antiapoptotic molecule c-FLIP(L). c-Fos binds the c-FLIP(L) promoter, represses its transcriptional activity, and reduces c-FLIP(L) mRNA and protein levels. Therefore, c-Fos is a key regulator of c-FLIP(L), and activation of c-Fos determines whether a cancer cell will undergo cell death after TRAIL treatment. Strategies to activate c-Fos or inhibit c-FLIP(L) may potentiate TRAIL-based proapoptotic therapies.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17909052 PMCID: PMC2941899 DOI: 10.1158/0008-5472.CAN-07-1310
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701